Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
First Claim
Patent Images
1. A method of promoting production of a human Huntingtin protein lacking a proteolytic caspase-6 cleavage site in a human cell, the method comprising:
- a) providing a human cell that expresses a human Huntingtin protein comprising a caspase-6 proteolytic cleavage site from a pre-mRNA encoding the protein, with an antisense oligonucleotide thatis directed toward the interior of exon 12 of the human Huntingtin gene;
binds to the pre-mRNA to form a double-stranded nucleic acid complex; and
induces partial skipping of exon 12,wherein at least nucleotides 207 to 341 of exon 12 are skipped;
wherein each nucleotide of the antisense oligonucleotide is chemically modified to render the double-stranded nucleic acid complex RNase H resistant; and
b) allowing translation of mRNA produced from the pre-mRNA in the cell to produce an mRNA lacking nucleotides 207 to 341 of exon 12;
wherein the anti-sense oligonucleotide comprises or consists of a sequence selected from SEQ ID NO;
178 and 182.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
30 Citations
4 Claims
-
1. A method of promoting production of a human Huntingtin protein lacking a proteolytic caspase-6 cleavage site in a human cell, the method comprising:
-
a) providing a human cell that expresses a human Huntingtin protein comprising a caspase-6 proteolytic cleavage site from a pre-mRNA encoding the protein, with an antisense oligonucleotide that is directed toward the interior of exon 12 of the human Huntingtin gene; binds to the pre-mRNA to form a double-stranded nucleic acid complex; and induces partial skipping of exon 12, wherein at least nucleotides 207 to 341 of exon 12 are skipped; wherein each nucleotide of the antisense oligonucleotide is chemically modified to render the double-stranded nucleic acid complex RNase H resistant; and b) allowing translation of mRNA produced from the pre-mRNA in the cell to produce an mRNA lacking nucleotides 207 to 341 of exon 12; wherein the anti-sense oligonucleotide comprises or consists of a sequence selected from SEQ ID NO;
178 and 182.- View Dependent Claims (2)
-
-
3. A method for treating Huntington'"'"'s disease in an individual, the method comprising:
-
administering to an individual in need thereof an antisense oligonucleotide directed toward the interior of exon 12 of the human Huntingtin gene that binds to a pre-mRNA produced from the human Huntingtin gene to form a double-stranded nucleic acid complex, and induces partial skipping of exon 12 of the human Huntingtin gene wherein at least nucleotides 207 to 341 of exon 12 are skipped; wherein each nucleotide of the antisense oligonucleotide is chemically modified to render the double-stranded nucleic acid complex RNase H resistant; and wherein the anti-sense oligonucleotide comprises or consists of a sequence selected from SEQ ID NO;
178 and 182. - View Dependent Claims (4)
-
Specification